An economic and quality‐of‐life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation
2001; Oxford University Press; Volume: 16; Issue: 5 Linguagem: Inglês
10.1093/ndt/16.5.1028
ISSN1460-2385
AutoresDaniel Polsky, Kevin P. Weinfurt, Bruce Kaplan, Jennifer Kim, John Fastenau, Kevin A. Schulman,
Tópico(s)Pregnancy and Medication Impact
ResumoBackground. Immunosuppressive therapy with cyclosporin A has substantially improved clinical outcomes for renal transplantation. Whether basiliximab (a chimeric monoclonal antibody) demonstrates economic and quality‐of‐life advantages over other induction therapies has not yet been shown.
Referência(s)